Characterization of the P95 cellular component phosphorylated on tyrosine after activation of the C3d/Epstein-Barr virus receptor (gp140, CR2, CD21) on human B lymphocytes

Author： Barel M.   Frade R.  

Publisher： Elsevier

ISSN： 0162-3109

Source： Immunopharmacology, Vol.49, Iss.1, 2000-08, pp. : 50-50

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Antithymocyte globulin/cyclophosphamide/muromonab CD3: Epstein-Barr virus lymphoproliferative disease: case report

By  

Reactions Weekly, Vol. 1, Iss. 1180, 2007-01 ,pp. : 4-5

Adis International

Access to resources Recommend Favorite

Romidepsin: First reports of Epstein-Barr virus infection and hepatitis B reactivation: 3 case reports

By  

Reactions Weekly, Vol. 1, Iss. 1291, 2010-01 ,pp. : 40-41

Adis International

Access to resources Recommend Favorite

Deregulation of the cell cycle machinery by Epstein––Barr virus nuclear antigen 3C

By Kumar Pankaj   Murakami Masanao   Kaul Rajeev   Saha Abhik   Cai Qiliang   Robertson Erle S  

Future Virology, Vol. 4, Iss. 1, 2009-01 ,pp. : 79-91

Future Medicine

Access to resources Recommend Favorite

P2Y 11 receptor expression by human lymphocytes: evidence for two cAMP-linked purinoceptors

By Conigrave A.D.   Fernando K.C.   Gu B.   Tasevski V.   Zhang W.   Luttrell B.M.   Wiley J.S.  

European Journal of Pharmacology, Vol. 426, Iss. 3, 2001-08 ,pp. : 157-163

Elsevier

Access to resources Recommend Favorite

Methotrexate: Epstein-Barr virus-associated B-cell lymphoma: case report

By  

Reactions Weekly, Vol. 1, Iss. 1196, 2008-01 ,pp. : 29-30

Adis International

Access to resources Recommend Favorite